Calithera Biosciences IncOOTC CALA Stock Report

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The firm is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The firm is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The firm is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The firm's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.